Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients undergoing aortic valve replacement for severe aortic stenosis: a retrospective cohort study
Abid, Husnain Khan, Yusuf Khan, Nazish Khan, Jawad Steeds, Richard Paul
Abid, Husnain
Khan, Yusuf
Khan, Nazish
Khan, Jawad
Steeds, Richard Paul
Abstract
Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) were historically considered contraindicated in severe aortic stenosis (AS) due to theoretical haemodynamic risks. Contemporary evidence increasingly challenges this paradigm, yet data on preoperative use and postoperative outcomes remain limited. We examined the association between preoperative ACEi/ARB use and mortality following aortic valve replacement. We conducted a retrospective cohort study of 198 consecutive patients undergoing transcatheter (TAVI) or surgical aortic valve replacement (SAVR) at a single tertiary centre between May 2020 and March 2025. Complete one-year follow up was available for 185 patients (93%). The primary outcome was one-year all-cause mortality. Multivariable logistic regression adjusted for age, sex, hypertension, diabetes, LVEF, and procedure type. Of 198 patients, 80 (40%) were receiving ACEi/ARB therapy preoperatively. ACEi/ARB users had a higher prevalence of hypertension (82% vs. 53%, < 0.001) and diabetes (48% vs. 27%, = 0.005) but similar age, valve area, and ejection fraction. Unadjusted one-year mortality was lower in the ACEi/ARB group (7% vs. 19%; odds ratio [OR] 0.33, 95% CI 0.12-0.91, = 0.030). After multivariable adjustment for confounders including age, diabetes, and hypertension, the association did not reach statistical significance (adjusted OR 0.33, 95% CI 0.10-1.12, = 0.075). Among diabetic patients, unadjusted one-year mortality was numerically lower in the ACEi/ARB group (12% vs. 35%, = 0.038); however, six subgroup comparisons were performed and this result would not survive Bonferroni correction (threshold < 0.008). This exploratory finding should be interpreted with caution given the small sample size and absence of adjustment for confounders. Preoperative ACEi/ARB use was associated with lower unadjusted one-year mortality, but this association did not reach statistical significance after multivariable adjustment and residual confounding cannot be excluded. ACEi/ARB use was not associated with increased mortality in this cohort. These hypothesis-generating findings from a single-centre observational study require confirmation in adequately powered prospective trials.
MIDER Authors
Affiliations
Sandwell and West Birmingham NHS Trust; University Hospitals Birmingham NHS Foundation Trust
Date
2026-04-10
Type
Article
Collections
Citation
Abid H, Khan Y, Khan N, Khan J, Steeds RP. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Undergoing Aortic Valve Replacement for Severe Aortic Stenosis: A Retrospective Cohort Study. J Clin Med. 2026 Apr 10;15(8):2904. doi: 10.3390/jcm15082904